BCD-261

Originator investigational product
List of clinical studies

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are chronic immunoinflammatory diseases of unknown etiology, which are characterized by inflammatory destructive damage to the intestinal wall and a chronic relapsing course involving systemic and extraintestinal complications1.

The originator investigational product BCD-261 is a monoclonal antibody being developed for the treatment of inflammatory bowel disease.

A monoclonal antibody is a protein created by scientists in the laboratory, similar to the immune system natural antibodies, designed to bind to a specific target in the human body2.

The target of the product under developed, BCD-261, is proinflammatory cytokine TL1A3, which has a negative effect on the Crohn's disease and ulcerative colitis4.

BCD-261 is one of the drug products in the clinical development program of BIOCAD.

  • Knyazev O. V., Shkurko T. V., Kagramanova A. V., Veselov A. V., Nikonov E. L. Epidemiologiya vospalitel'nykh zabolevaniy kishechnika. Sovremennoye sostoyaniye problemy (obzor literatury). Dokazatel'naya gastroenterologiya. 2020;9(2):66 73.
  • Weiner L. M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
  • TL1A, TNF-like ligand 1A.
  • Bamias G., Martin C., 3rd, Marini M., Hoang S., Mishina M., Ross W. G., et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171(9):4868-74.

This site section includes information about an unauthorized investigational drug product for human use.